| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Pullicino), State University of New York at Buffalo; The Zena and Michael A. Wiener Cardiovascular Institute (Dr. Halperin), Mount Sinai Medical Center, New York, NY; and the Division of Biostatistics (Dr. Thompson), School of Public Health, Columbia University, New York, NY.
Address correspondence and reprint requests to Dr. Patrick Pullicino, Stroke Service, Department of Neurology, Buffalo General Hospital, 100 High Street, Buffalo, NY 14203.
BACKGROUND: Cardiac failure is associated with both stroke of presumed cardioembolic origin and a high mortality rate. Warfarin is used frequently in patients with reduced cardiac left ventricular ejection fraction (EF), although no randomized trials have confirmed that anticoagulation benefits these patients.
METHODS: A literature review was performed pertaining to the frequency of stroke and mortality, and the effect of antithrombotic agents on stroke and mortality rates, in patients with cardiac failure or reduced cardiac EF. We also reviewed the main features of two new proposed studies (Warfarin and Antiplatelet Therapy in Chronic Heart Failure [WATCH] and Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction [WARCEF]) comparing warfarin and antiplatelet agents in patients with low EF.
RESULTS: The risk of stroke increases with decreasing EF and the risk of mortality increases with the clinical severity of cardiac failure (New York Heart Association class). Data from heart failure treatment studies suggest that warfarin may reduce stroke and mortality in patients with reduced EF, but definitive answers are lacking. The stroke rate alone is too low to be used as a primary endpoint, but an endpoint combining stroke and death (as WARCEF and WATCH propose) should allow an assessment of the effect of antithrombotics in cardiac failure. Amalgamating the data on stroke from these two trials should yield enough statistical power to compare the effects of warfarin and aspirin on stroke as an independent secondary endpoint.
CONCLUSION: Whether warfarin is superior to aspirin in reducing stroke and mortality in patients with low ejection fraction is an important clinical issue that warrants prospective evaluation.
Key words: Stroke—Heart failure—Ejection fraction—Warfarin—Aspirin
This article has been cited by other articles:
|
|
 |
|
  M. S. Slaughter, J. G. Rogers, C. A. Milano, S. D. Russell, J. V. Conte, D. Feldman, B. Sun, A. J. Tatooles, R. M. Delgado III, J. W. Long, et al. Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device N. Engl. J. Med., November 17, 2009; (2009) NEJMoa0909938v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Aull-Watschinger, H. Konstantin, D. Demetriou, M. Schillinger, A. Habicht, W. H. Horl, and B. Watschinger Pre-transplant predictors of cerebrovascular events after kidney transplantation Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1429 - 1435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Doufekias, A. Z. Segal, and J. R. Kizer Cardiogenic and aortogenic brain embolism. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1049 - 1059. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Bierig, A. Ryan, A. Ziaee, L. Kociolek, J. Simon, S. Herrmann, and A. J. Labovitz Serial changes in systolic and diastolic echocardiographic indices as predictors of outcome in patients with decreased left ventricular ejection fraction Eur J Echocardiogr, October 1, 2007; 8(5): 369 - 374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L.C. Vogels, W. M. van der Flier, B. van Harten, A. A. Gouw, P. Scheltens, J. M. Schroeder-Tanka, and H. C. Weinstein Brain magnetic resonance imaging abnormalities in patients with heart failure Eur J Heart Fail, October 1, 2007; 9(10): 1003 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. K. Sampson, M. A. Pfeffer, J. J.V. McMurray, Y. Lokhnygina, H. D. White, S. D. Solomon, and for the Valsartan in Acute Myocardial iNfarcTion ( Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT trial Eur. Heart J., March 2, 2007; 28(6): 685 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Hays, R. L. Sacco, T. Rundek, R. R. Sciacca, Z. Jin, R. Liu, S. Homma, and M. R. Di Tullio Left Ventricular Systolic Dysfunction and the Risk of Ischemic Stroke in a Multiethnic Population Stroke, July 1, 2006; 37(7): 1715 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Blankfield Can Natriuretic Peptide Levels Predict the Cardiovascular Complications of COX-2 Inhibitors and Nonsteroidal Anti-inflammatory Drugs? J Am Board Fam Med, March 1, 2006; 19(2): 178 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T. Yan, R. T. Yan, and P. P. Liu Narrative Review: Pharmacotherapy for Chronic Heart Failure: Evidence from Recent Clinical Trials Ann Intern Med, January 18, 2005; 142(2): 132 - 145. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Lazar, P. A. Shapiro, B. E. Jaski, M. K. Parides, R. C. Bourge, J. T. Watson, L. Damme, W. Dembitsky, J. D. Hosenpud, L. Gupta, et al. Neurological Events During Long-Term Mechanical Circulatory Support for Heart Failure: The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Experience Circulation, May 25, 2004; 109(20): 2423 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J. Am. Coll. Cardiol., May 7, 2003; 41(9): 1633 - 1652. [Full Text] [PDF]
|
|
|
|
|
|
J. Hirsh, V. Fuster, J. Ansell, and J. L. Halperin American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy Circulation, April 1, 2003; 107(12): 1692 - 1711. [Full Text] [PDF]
|
|
|
|
|
|
P. Appelros, I. Nydevik, and M. Viitanen Poor Outcome After First-Ever Stroke: Predictors for Death, Dependency, and Recurrent Stroke Within the First Year Stroke, January 1, 2003; 34(1): 122 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Echemann, F. Alla, S. Briancon, Y. Juilliere, J.M. Virion, P.M. Mertes, J.P. Villemot, F. Zannad, and EPICAL Investigators Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) Eur J Heart Fail, October 1, 2002; 4(5): 647 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Appelros, I. Nydevik, A. Seiger, and A. Terent Predictors of Severe Stroke: Influence of Preexisting Dementia and Cardiac Disorders Stroke, October 1, 2002; 33(10): 2357 - 2362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Morris, J. D. Vega, J. H. Levy, N. N. Buist, A. L. Smith, G. J. Despotis, and K. R. Kanter Warfarin therapy does not increase bleeding in patients undergoing heart transplantation Ann. Thorac. Surg., September 1, 2001; 72(3): 714 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomberg-Maitland, D. A. Baran, and V. Fuster Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist Arch Intern Med, February 12, 2001; 161(3): 342 - 352. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
